Skip to main content

Advertisement

Log in

Management of patients with chronic kidney disease

  • SELECTED PAPERS - SUBCLINICAL RENAL INSUFFICIENCY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is a silent disease which worsens gradually to end-stage kidney disease (ESKD). US kidney disease outcomes quality initiative (KDOQI) guidelines indicate five stages of CKD based on the severity of kidney function which is assessed by estimating the glomerular filtration rate (GFR) by the modification of diet in renal disease (MDRD) formula. The management of CKD patients with mild renal damage (stage 1–2 KDOQI) is articulated on the reduction of proteinuria (<500 mg/day), reduction of sitting systolic and diastolic blood pressure (<130/80 mmHg), salt restriction diet, diuretics (furosemide, spironolactone), antihypertensive agents (ACE inhibitors or ARBs (angiotensin II receptor blockers) or both as first-line therapy), additional other antihypertensives (aliskiren, non-dihydropyridine calcium channel blockers, beta blockers), body weight reduction, cigarette smoking stopping, allopurinol therapy and non-use of some drugs (non-steroidal anti-inflammatory agents, acetaminophen, bisphosphonates, oral estrogens) and herbals. The management of CKD patients with moderate-severe renal damage (stage 3–5 KDOQI) is based on the above recommendations plus low protein diet, correction of hyperkalaemia, metabolic acidosis, and administration of vitamin D derivates and erythropoietin for the correction of mineral metabolism disorders and anemia, respectively. In conclusion, patients with CKD (stage 1–2 KDOQI) may be correctly managed by primary care physicians, individuals in stage 3–5 KDOQI need the supervision of nephrologists to assess those patients who progress to ESKD and require renal replacement therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. National Kidney Foundation (2002) KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 1):S1–S266

    Google Scholar 

  2. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P (2005) Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16:763–773

    Article  PubMed  Google Scholar 

  3. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483

    Article  PubMed  CAS  Google Scholar 

  4. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang YL, Coresh J, Levey AS (2009) Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75:652–660

    Article  PubMed  CAS  Google Scholar 

  5. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252–1256

    Article  PubMed  CAS  Google Scholar 

  6. Hallan S, Asberg A, Lindberg M, Johnsen H (2004) Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 44:84–93

    Article  PubMed  Google Scholar 

  7. National Kidney Foundation (2002) KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 2):S1–S266

    Google Scholar 

  8. Carattino MD, Passero CJ (2011) Clues to renal sodium retention. Am J Physiol Renal Physiol 300:F639–F640

    Article  PubMed  CAS  Google Scholar 

  9. Choi ME (2009) The not-so-sweet side of fructose. J Am Soc Nephrol 20:457–459

    Article  PubMed  Google Scholar 

  10. Cianciaruso B, Bellizzi V, Minutolo R, Colucci G, Bisesti V, Russo D, Conte G, De Nicola L (1996) Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease. J Am Soc Nephrol 7:306–313

    PubMed  CAS  Google Scholar 

  11. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:542–551

    Article  PubMed  CAS  Google Scholar 

  12. Beddhu S (2004) The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. Semin Dial 17:229–232

    Article  PubMed  Google Scholar 

  13. Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004) The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141:95–101

    PubMed  Google Scholar 

  14. Hallan SI, Orth SR (2011) Smoking is a risk factor in the progression to kidney failure. Kidney Int [Epub ahead of print]

  15. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557–1563

    Article  PubMed  CAS  Google Scholar 

  16. Arici M, Erdem Y (2009) Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 53:332–345

    Article  PubMed  CAS  Google Scholar 

  17. Cravedi P, Ruggenenti P, Remuzzi G (2009) Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep 11:118–124

    Article  PubMed  CAS  Google Scholar 

  18. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939–945

    Article  PubMed  CAS  Google Scholar 

  19. Anderson S, Komers R (2008) Aliskiren combined with losartan in diabetes and nephropathy. N Engl J Med 359:1069

    Article  PubMed  CAS  Google Scholar 

  20. Gashti CN, Bakris GL (2004) The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 13:155–161

    Article  PubMed  CAS  Google Scholar 

  21. Bakris GL, Hart P, Ritz E (2006) Beta blockers in the management of chronic kidney disease. Kidney Int 70:1905–1913

    PubMed  CAS  Google Scholar 

  22. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393

    Article  PubMed  CAS  Google Scholar 

  23. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226–232

    Article  PubMed  CAS  Google Scholar 

  24. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O (2001) Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345:1801–1808

    Article  PubMed  CAS  Google Scholar 

  25. Menon V, Kopple JD, Wang X, Beck GJ, Collins AJ, Kusek JW, Greene T, Levey AS, Sarnak MJ (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 53:208–217

    Article  PubMed  CAS  Google Scholar 

  26. Thompson AM, Pickering TG (2006) The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease. Kidney Int 70:1000–1007

    Article  PubMed  CAS  Google Scholar 

  27. Fink JC (2010) Chronic kidney disease: the effect of CKD therapies on serum potassium levels. Nat Rev Nephrol. 6:633–634

    Article  PubMed  Google Scholar 

  28. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16:1803–1810

    Article  PubMed  Google Scholar 

  29. Weisbord SD, Kimmel PL (2008) Health-related quality of life in the era of erythropoietin. Hemodial Int 12:6–15

    Article  PubMed  Google Scholar 

  30. Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388

    Article  PubMed  CAS  Google Scholar 

  31. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC (2007) Haemoglobin targets: we were wrong, time to move on. Lancet 369:346–350

    Article  PubMed  Google Scholar 

  32. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953

    Article  PubMed  CAS  Google Scholar 

  33. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J (2004) Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 65:1031–1040

    Article  PubMed  CAS  Google Scholar 

  34. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesco P. Schena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schena, F.P. Management of patients with chronic kidney disease. Intern Emerg Med 6 (Suppl 1), 77 (2011). https://doi.org/10.1007/s11739-011-0688-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11739-011-0688-2

Keywords

Navigation